






# KRIBIOLISA™ Ranibizumab (Lucentis™) ELISA

**REF** : KBI1029-4

Ver 1.0


**RUO**

Enzyme Immunoassay for the quantitative determination of Ranibizumab in serum and plasma. This kit measures specifically the bound drug (Ranibizumab) complex.

<b>RUO</b>	For Research Use Only	<b>REF</b>	Catalog Number
	Store At	<b>LOT</b>	Batch Code
	Manufactured By		Biological Risk
	Expiry Date		Consult Operating Instructions

*For Research Use Only. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN BioSystems is strictly prohibited.*

**REF** KBI1029-4

 96 tests



**KRISHGEN BioSystems** | For US / Europe: toll free +1(888)-970-0827 tel: +1(562)-568-5005  
For Asia / India: tel: +91(22)-49198700  
Email: sales@krishgen.com

**Introduction:**

Ranibizumab (Lucentis) is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). VEGF is a biochemical signal protein that promotes angiogenesis throughout the body and in the eye. Through binding to VEGF-A, ranibizumab interrupts the interaction of VEGF with its receptors, and thus prevents the subsequent growth of new blood vessels.


This kit KRIBIOLISA™ Ranibizumab (Lucentis™) ELISA specifically recognizes Ranibizumab only when bound to its target, human VEGF-A. It does not recognize free human VEGF-A or bevacizumab. The kit can be used to measure levels of bound Ranibizumab and biosimilars in patient samples.

**Intended Use:**

The KRIBIOLISA™ Ranibizumab (Lucentis™) ELISA is used as an analytical tool for quantitative determination of Ranibizumab in serum and plasma. The kit measures bound Ranibizumab complex.

**Principle:**

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Ranibizumab are pre-coated onto microwells. HRP Conjugate, Samples / Standards are pipetted into microwells and human Ranibizumab present in the sample are bound by the capture antibody. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Ranibizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

**Materials Provided:**

Part	Description	Qty
Anti-Ranibizumab Coated Microtiter Plate	96 well polystyrene microplate (12 strips of 8 wells) coated with Anti-Ranibizumab monoclonal antibody.	1 x 96 wells
Ranibizumab Standard	Ranibizumab in a buffered protein with protein stabilizer and preservatives 0.02% methylisothiazolone and 0.02% bromonitrodioxane - 0.5 ml each (0, 10, 20, 40, 80, 160 and 320 ng/ml)	7 vials
Anti-Ranibizumab:HRP Conjugate	Anti-Ranibizumab conjugated to Horseradish Peroxidase with protein stabilizer and preservatives 0.02% methylisothiazolone and 0.02% bromonitrodioxane.	12 ml
(1X) Sample Diluent	Buffered protein base with preservative thiomersol < 0.01%	25 ml
(20X) Wash Buffer	20-fold concentrated solution of buffered surfactant with preservative thiomersol < 0.01%. May turn yellow over time.	25 ml
TMB Substrate	Stabilized Chromogen	12 ml
Stop Solution	2N Sulfuric Acid	12 ml
Instruction Manual		1 no

**Materials to be provided by the End-User:**

1. Microtiter Plate Reader able to measure absorbance at 450 nm.

2. Adjustable pipettes and multichannel pipettor to measure volumes ranging from 25 ul to 1000 ul
3. Deionized (DI) water
4. Wash bottle or automated microplate washer
5. Graph paper or software for data analysis
6. Timer
7. Absorbent Paper

**Handling/Storage:**

1. All reagents should be stored at 2°C to 8°C for stability.
2. All the reagents and wash solutions should be used within 12 months from manufacturing date.
3. Before using, bring all components to room temperature (18-25°C). Upon assay completion ensure all components of the kit are returned to appropriate storage conditions.
4. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

**Health Hazard Warnings:**

1. Reagents that contain preservatives may be harmful if ingested, inhaled or absorbed through the skin.
2. For Research Use Only.

**Sample Preparation and Storage:**

Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. If samples are to be used for several assays, initially aliquot samples and keep at -20°C.

**Preparation before Use:**

Allow samples to reach room temperature prior to assay. Take care to agitate patient samples gently in order to ensure homogeneity.

Test Sample preparation - Samples have to be diluted 1:100 (v/v), e.g. for 1:100 (1 ul sample + 99 ul sample diluent) prior to assay. The samples may be kept at 2 - 8°C for up to three days. Long-term storage requires -20°C.

**Reagent Preparation (all reagents should be diluted immediately prior to use):**

1. Label any aliquots made with the kit Lot No and Expiration date and store it at appropriate conditions mentioned.
2. Bring all reagents to Room temperature before use.
3. To make Wash Buffer (1X); dilute 25 ml of 20X Wash Buffer in 475 ml of DI water.

**Procedural Notes:**

1. In order to achieve good assay reproducibility and sensitivity, proper washing of the plates to remove excess un-reacted reagents is essential.
2. High Dose Hook Effect may be observed in samples with very high concentrations of Ranibizumab. High Dose Hook Effect is due to excess of antibody for very high concentrations of Ranibizumab present in the sample. High Dose Hook effect is most likely encountered from samples early in the purification process. If Hook Effect is possible, the samples to be assayed should be diluted with a compatible diluent. Thus if the Ranibizumab concentration of the undiluted sample is less than the diluted sample, this may be indicative of the Hook Effect.
3. Avoid assay of Samples containing sodium azide (NaN<sub>3</sub>), as it could destroy the HRP activity resulting in under-estimation of the amount of Ranibizumab.
4. It is recommended that all Standards and Samples be assayed in duplicates.
5. Maintain a repetitive timing sequence from well to well for all the steps to ensure that the incubation timings are same for each well.

6. If the Substrate has a distinct blue color prior to use it may have been contaminated and use of such substrate can lead to compromise of the sensitivity of the assay.
7. The plates should be read within 30 minutes after adding the Stop Solution.
8. Make a work list in order to identify the location of Standards and Samples.

**Assay Procedure:**

1. It is strongly recommended that all Standards and Samples be run in duplicates. A standard curve is required for each assay. All steps must be performed at 37°C
2. Add **100 ul** of **Standards** or **Samples** into the respective wells.
3. Cover the plate and incubate for 60 minutes at 37°C.
4. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
5. Add **100 ul** of **Anti-Ranibizumab:HRP Conjugate** into the each well.
6. Cover the plate and incubate for 60 minutes at 37°C
7. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
8. Add **100 ul** of **TMB Substrate** in each well.
9. Incubate the plate at 37°C for 30 minutes in dark. DO NOT SHAKE or else it may result in higher backgrounds and worse precision. Positive wells should turn bluish in color.
10. Pipette out **100 ul** of **Stop Solution**. Wells should turn from blue to yellow in color.
11. Read the absorbance at 450 nm with a microplate reader.

**Calculation of Results:**

Determine the Mean Absorbance for each set of duplicate or triplicate Standards and Samples. Using graph paper, plot the average value (absorbance 450nm) of each standard on the Y-axis versus the corresponding concentration of the standards on the X-axis. Draw the best fit curve through the standard points. To determine the unknown bound Ranibizumab concentrations, find the unknown's Mean Absorbance value on the Y-axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the X-axis and read the Ranibizumab Concentration. If samples were diluted, multiply by the appropriate dilution factor.

Software which is able to generate a curve with polynomial regression (2<sup>nd</sup> order), 4PL or cubic spline to interpret the data is recommended.

**Note:**


It is recommended to repeat the assay at a different dilution factor in the following cases:

- If the sample absorbance value is below the first standard.
- If the absorbance value is equivalent or higher than the 320 ng/ml standard.

## Typical Data

Standard Concentration (ng/ml)	Mean Absorbance	Interpolated Concentration	% Interpolated Concentration against Actual Concentration
0	0.074	--	--
10	0.177	11.2	111.7
20	0.306	24.6	123.0
40	0.536	42.6	106.5
80	0.978	74.1	92.6
160	1.959	167.5	104.7
320	2.605	312.6	97.7

## Typical Graph



## Quality Control:

It is recommended that for each laboratory assay appropriate quality control samples in each run to be used to ensure that all reagents and procedures are correct.

## Performance Characteristics of the Kit:

This kit has been validated as per EMA/FDA guidelines in line with ICH Code for Harmonization of Biological Assays.

## Sensitivity:

**Limit Of Detection:** It is defined as the lowest detectable concentration corresponding to a signal of Mean of '0' standard plus 2\* SD.

10 replicates of '0' standards were evaluated and the LOD was found to be 8.5 ng/ml

## Specificity:

The antibodies used in the kit are monoclonal antibodies, anti-idiotypic and specific for Ranibizumab. The calibrators / standards used are calibrated against commercially sourced (Lucentis™).

## Linearity:

Standards provided in the kit were tested with Sample Diluent at different dilution ratios and recoveries obtained were measured for normal human serum and plasma.

Serum diluted with Sample Diluent	Standard (ng/ml)	Mean Abs	Interpolated Concentration	% Interpolated Concentration against Actual Concentration
1:10 serum	0	0.383	--	--
	640	3.136	391.4	61.2
1:100 serum	0	0.154	--	--
	640	3.346	673.2	105.2

Serum diluted with Sample Diluent	Standard (ng/ml)	Mean Abs	Interpolated Concentration	% Interpolated Concentration against Actual Concentration
1:500 serum	0	0.114	--	--
	640	3.159	410.7	64.2
1:1000 serum	0	0.109	--	--
	640	3.274	541.8	84.6
1:2000 serum	0	0.098	--	--
	640	3.075	347.3	54.3
1:5000 serum	0	0.091	--	--
	640	2.981	294.5	46.0

Plasma diluted with Sample Diluent	Standard (ng/ml)	Mean Abs	Interpolated Concentration	% Interpolated Concentration against Actual Concentration
1:10 plasma	0	0.482	--	--
	640	3.323	625.0	97.7
<b>1:100 plasma</b>	<b>0</b>	<b>0.193</b>	<b>--</b>	<b>--</b>
	<b>640</b>	<b>3.312</b>	<b>604.2</b>	<b>94.4</b>
1:500 plasma	0	0.152	--	--
	640	3.281	552.3	86.3
1:1000 plasma	0	0.139	--	--
	640	3.269	534.5	83.5
1:2000 plasma	0	0.117	--	--
	640	3.299	581.3	90.8
1:5000 plasma	0	0.096	--	--
	640	3.311	602.4	94.1

**Precision:**

Precision is defined as the percent coefficient of variation (%CV) i.e. standard deviation divided by the mean and multiplied by 100. Assay precision was determined by both intra (n=5 assays) and inter assay (n=5 assays) reproducibility on two pools with low (10ng/ml), medium (80 ng/ml) and high (640 ng/ml) concentrations. While actual precision may vary from laboratory to laboratory and technician to technician, it is recommended that all operators achieve precision below these design goals before reporting results.

Pool	Intra Assay %CV	Inter Assay %CV
Low	<12%	<10%
Medium	<10%	<10%
High	<10%	<10%

**Safety Precautions:**

- **This kit is for Research Use Only.** Follow the working instructions carefully.
- The expiration dates stated on the kit are to be observed. The same relates to the stability stated for reagents
- Do not use or mix reagents from different lots.
- Do not use reagents from other manufacturers.
- Avoid time shift during pipetting of reagents.
- All reagents should be kept in the original shipping container.
- Some of the reagents contain small amount of sodium azide (< 0.1 % w/w) as preservative. They must not be swallowed or allowed to come into contact with skin or mucosa.
- Source materials maybe derived from human body fluids or organs used in the preparation of this kit were tested and found negative for HBsAg and HIV as well as for HCV antibodies. However, no known test guarantees the absence of such viral agents. Therefore, handle all components and all patient samples as if potentially hazardous.
- Since the kit contains potentially hazardous materials, the following precautions should be observed



- Do not smoke, eat or drink while handling kit material
- Always use protective gloves
- Never pipette material by mouth
- Wipe up spills promptly, washing the affected surface thoroughly with a decontaminant.
- In any case GLP should be applied with all general and individual regulations to the use of this kit.

**References:**

Serum and Plasma Vascular Endothelial Growth Factor Concentrations Before and After Intravitreal Injection of Aflibercept or Ranibizumab for Age-Related Macular Degeneration...Wang X, Sawada T, Sawada O....Am J Ophthalmol...2014...Elsevier

Ranibizumab and aflibercept:intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes...Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M...Invest Ophthalmol Vis Sci...2015...ARVO

Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema... Yi Zhang, Zhenling Yao, Nitin Kaila, Peter Kuebler...Ophthalmology...2014...American Academy of Ophthalmology

Evaluation of fluorophotometry to assess the vitreal pharmacokinetics of protein therapeutics... Dickmann LJ, Yip V, Li C...Invest Ophthalmol Vis Sci...2015... ARVO


Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab...Graefes Ying Zhou, Yanrong Jiang, Yujing Bai, Jing Wen, Li Chen...Arch Clin Exp Ophthalmol...2016... Springer

**SCHEMATIC ASSAY PROCEDURE**

1. Remove all components, 30 minutes before adding into the assay plate.



2. Avoid repeated cool-thaw of the components as there will be a loss of activity and this can affect the results.



3. Pipette **100 ul Standards / Samples** into the respective wells

4. Cover plate and incubate for at 37°C

5. Aspirate and wash wells 4 times with **Wash Buffer (1X)**

6. Pipette **100 ul Anti-Ranibizumab: HRP** into each well

7. Cover plate and incubate for at 37°C

8. Aspirate and wash wells 4 times with **Wash Buffer (1X)**

9. Pipette **100ul TMB Substrate** into each well

10. Cover plate and incubate for at 37°C.

11. Pipette **100ul Stop Solution** into each well.

12. Read absorbance at 450nm with a microplate reader within of stopping reaction.



**Typical Example of a Work List**

Well #	Contents	Absorbance at 450nm	Mean Absorbance	ng/ml Ranibizumab equivalent
1A	zero std			
2A	zero std			
1B	10 ng/ml			
2B	10 ng/ml			
1C	20 ng/ml			
2C	20 ng/ml			
1D	40 ng/ml			
2D	40 ng/ml			
1E	80 ng/ml			
2E	80 ng/ml			
1F	160 ng/ml			
2F	160 ng/ml			
1G	320 ng/ml			
2G	320 ng/ml			
3A	Sample			
4A	Sample			
3B	Sample			
4B	Sample			

**LIMITED WARRANTY**

Krishgen Biosystems does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the Products; against defects in products or components not manufactured by Krishgen Biosystems, or against damages resulting from such non-Krishgen Biosystems made products or components. Krishgen Biosystems passes on to customer the warranty it received (if any) from the maker thereof of such non Krishgen made products or components. This warranty also does not apply to Products to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Biosystems.

THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Biosystems shall be to repair or replace the defective Products in the manner and for the period provided above. Krishgen Biosystems shall not have any other obligation with respect to the Products or any part thereof, whether based on contract, tort, and strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Biosystems be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Biosystems with respect to the Products. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.












Krishgen Biosystems. 2021

**THANK YOU FOR USING KRISHGEN PRODUCT!**

KRISHGEN BIOSYSTEMS®, GENLISA®, DHARMAPLEX™, GENBULK™, GENLISA™, KRISHZYME®, KRISHGEN®, KRIBIOLISA®, KRISHPLEX®, TITANIUM®, QUALICHEK® are registered trademarks of KRISHGEN BIOSYSTEMS. ©KRISHGEN BIOSYSTEMS. ALL RIGHTS RESERVED.

KRISHGEN BIOSYSTEMS | OUR REAGENTS | YOUR RESEARCH |

## SYMBOLS KEY

	Anti-Ranibizumab Microtiter Plate (12x8 wells)
	Ranibizumab Standards
	Anti- Ranibizumab:HRP Conjugate
	(1X) Sample Diluent
	(20X) Wash Buffer
	TMB Substrate
	Stop Solution
	Consult Instructions for Use
	Catalog Number
	Expiration Date
	Storage Temperature